Table 3.
Risk of high-grade cervical dysplasia or cervical cancer among SLE patients associated with initiation of immunosuppressive drugs versus hydroxychloroquine in a propensity-score matched analysis
| Immunosuppressive Drugs | Hydroxychloroquine | |||||||
|---|---|---|---|---|---|---|---|---|
| Cases | Person- years |
Incidence Rate* (95% CI) |
Hazard ratio (95% CI) |
Cases | Person- years |
Incidence Rate* (95% CI) |
Hazard ratio (95% CI) |
|
|
Commercial Health Plan |
14 | 2976 | 4.70 (2.78–7.94) |
2.47 (0.89–6.85) |
5 | 2646 | 1.89 (0.79–4.54) |
Ref. |
| Medicaid | 46 | 13,043 | 3.53 (2.64–4.71) |
1.24 (0.78–1.98) |
29 | 10,772 | 2.69 (1.87–3.87) |
Ref. |
| Pooled Analysis | 1.40 (0.92–2.12) |
Ref. | ||||||
*
Incidence rate per 1,000 person-years